Date: November 16, 2026
Clinical Development Update
Suven Life Sciences, a clinical-stage biopharmaceutical company focused on CNS disorders, announced it will present two scientific presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD-2026) Conference in Boston, USA during November 16-19, 2026.
Presentation Details
Masupirdine (SUVN-502) Presentation (P033)
- Presentation title: "Masupirdine (SUVN-502), A Pure 5-HT6 Receptor Antagonist: Baseline Demographic and Clinical Characteristics of the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer's Type"
- Will present baseline demographic and clinical characteristics of patients enrolled in the global Phase-3 study
- Enrollment in the global Phase-3 Masupirdine AAD study is complete
- Baseline characteristics are consistent with published studies and represent a quality AD population with Agitation
- No major safety concerns have been identified to date
- Topline results are scheduled for Q2 2027
Tenaclidine (SUVN-I6107) Presentation (P066)
- Presentation title: "Tenaclidine (SUVN-I6107), A Pure M1 Positive Allosteric Modulator First-in-Human Evaluation of Safety, Tolerability and Pharmacokinetics in Healthy Subjects"
- Will present outcomes from Phase-1 single ascending dose (SAD) and multiple ascending dose (MAD) studies in healthy subjects
- Includes safety, tolerability and pharmacokinetics data
- Includes effects of food, age and gender on pharmacokinetic profile
- Phase-1 study is completed
- Long term general toxicity and developmental toxicity studies in nonclinical models are in progress
Management Commentary
Mr. Venkat Jasti, Chairman and Managing Director, stated: "Completion of enrolment in the global Phase-3 Masupirdine AAD study marks an important milestone in the clinical development. Very glad to report the baseline characteristics are consistent with the published studies, representative of quality AD population with Agitation and no major safety concerns have been identified to date. We look forward to the topline results as scheduled in Q2-2027. We are very encouraged by the clinical findings for Tenaclidine, to move forward to the patient studies. The progress reflects our continued efforts to advance innovative therapeutic approaches addressing significant unmet needs in CNS disorders."
Company Pipeline Overview
Suven has 5 clinical stage assets across focus areas:
- Masupirdine (SUVN-502): For treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing, enrollment completed)
- Samelisant (SUVN-G3031): For excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; pivotal Phase-3 AWAKE study for EDS initiated; Phase-2 study for Cataplexy in planning)
- Ropanicant (SUVN-911): For MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study completed; Phase-3 study in planning)
- Usmarapride (SUVN-D4010): For cognitive disorders (Phase-2 study in planning)
- Tenaclidine (SUVN-I6107): For cognitive disorders (Phase-1 study completed)
In addition to these clinical assets, the company has seven projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major world markets.